Rational approach to the design of bioactive peptidomimetics: Recent developments in opioid agonist peptides

Adriano Mollica, Azzurra Stefanucci, Roberto Costante, Victor J Hruby

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pharmacological management of severe and chronic pain remains a difficult achievement with currently available analgesic drugs. The design and development of potent opioid analogs with reduced tolerance, dependence, respiratory depression, and other unwanted side effects, could be of great value in the clinical treatment of chronic pain. The hierarchical approach to peptidomimetic design has dramatically advanced over the past three decades; a significant target in research since the discovery of multiple opioid receptors has been to develop highly potent and selective opioid receptor peptidomimetics that overcome the problems related to scarce bioavailability, enzymatic degradation, and low safety profile of natural peptides. Peptide drug design is a high multidisciplinary area that often relies on the state-of-the-art of organic chemistry, pharmacology, and biochemistry, computational methods and biophysical methods for determining the structural, conformational, topographical, and dynamic properties of designed ligands. With the aim to explore the recent advancements in opioids research, in this chapter, particular attention has been paid on the structural modifications of natural opioid peptides to obtain potent, selective, and stable opioid agonists. In addition, we focused our attention on μ/δ mixed agonists and novel approaches based on multitarget ligands, as discussed in section "Future Perspectives and Conclusions."

Original languageEnglish (US)
Pages (from-to)27-68
Number of pages42
JournalStudies in Natural Products Chemistry
Volume46
DOIs
StatePublished - 2015

Fingerprint

Peptidomimetics
Opioid Peptides
Opioid Analgesics
Opioid Receptors
Chronic Pain
Peptides
Pharmacology
Organic Chemistry
Ligands
Biochemistry
Drug Design
Computational methods
Research
Respiratory Insufficiency
Biological Availability
Analgesics
Safety
Degradation
Pharmaceutical Preparations
Therapeutics

Keywords

  • opioid receptor agonists antinociceptive profile peptidomimetics topographical constraints structure-activity relationship

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery

Cite this

Rational approach to the design of bioactive peptidomimetics : Recent developments in opioid agonist peptides. / Mollica, Adriano; Stefanucci, Azzurra; Costante, Roberto; Hruby, Victor J.

In: Studies in Natural Products Chemistry, Vol. 46, 2015, p. 27-68.

Research output: Contribution to journalArticle

@article{9ccd2056549b4292a108533106e695e7,
title = "Rational approach to the design of bioactive peptidomimetics: Recent developments in opioid agonist peptides",
abstract = "Pharmacological management of severe and chronic pain remains a difficult achievement with currently available analgesic drugs. The design and development of potent opioid analogs with reduced tolerance, dependence, respiratory depression, and other unwanted side effects, could be of great value in the clinical treatment of chronic pain. The hierarchical approach to peptidomimetic design has dramatically advanced over the past three decades; a significant target in research since the discovery of multiple opioid receptors has been to develop highly potent and selective opioid receptor peptidomimetics that overcome the problems related to scarce bioavailability, enzymatic degradation, and low safety profile of natural peptides. Peptide drug design is a high multidisciplinary area that often relies on the state-of-the-art of organic chemistry, pharmacology, and biochemistry, computational methods and biophysical methods for determining the structural, conformational, topographical, and dynamic properties of designed ligands. With the aim to explore the recent advancements in opioids research, in this chapter, particular attention has been paid on the structural modifications of natural opioid peptides to obtain potent, selective, and stable opioid agonists. In addition, we focused our attention on μ/δ mixed agonists and novel approaches based on multitarget ligands, as discussed in section {"}Future Perspectives and Conclusions.{"}",
keywords = "opioid receptor agonists antinociceptive profile peptidomimetics topographical constraints structure-activity relationship",
author = "Adriano Mollica and Azzurra Stefanucci and Roberto Costante and Hruby, {Victor J}",
year = "2015",
doi = "10.1016/B978-0-444-63462-7.00002-6",
language = "English (US)",
volume = "46",
pages = "27--68",
journal = "Studies in Natural Products Chemistry",
issn = "1572-5995",
publisher = "Elsevier",

}

TY - JOUR

T1 - Rational approach to the design of bioactive peptidomimetics

T2 - Recent developments in opioid agonist peptides

AU - Mollica, Adriano

AU - Stefanucci, Azzurra

AU - Costante, Roberto

AU - Hruby, Victor J

PY - 2015

Y1 - 2015

N2 - Pharmacological management of severe and chronic pain remains a difficult achievement with currently available analgesic drugs. The design and development of potent opioid analogs with reduced tolerance, dependence, respiratory depression, and other unwanted side effects, could be of great value in the clinical treatment of chronic pain. The hierarchical approach to peptidomimetic design has dramatically advanced over the past three decades; a significant target in research since the discovery of multiple opioid receptors has been to develop highly potent and selective opioid receptor peptidomimetics that overcome the problems related to scarce bioavailability, enzymatic degradation, and low safety profile of natural peptides. Peptide drug design is a high multidisciplinary area that often relies on the state-of-the-art of organic chemistry, pharmacology, and biochemistry, computational methods and biophysical methods for determining the structural, conformational, topographical, and dynamic properties of designed ligands. With the aim to explore the recent advancements in opioids research, in this chapter, particular attention has been paid on the structural modifications of natural opioid peptides to obtain potent, selective, and stable opioid agonists. In addition, we focused our attention on μ/δ mixed agonists and novel approaches based on multitarget ligands, as discussed in section "Future Perspectives and Conclusions."

AB - Pharmacological management of severe and chronic pain remains a difficult achievement with currently available analgesic drugs. The design and development of potent opioid analogs with reduced tolerance, dependence, respiratory depression, and other unwanted side effects, could be of great value in the clinical treatment of chronic pain. The hierarchical approach to peptidomimetic design has dramatically advanced over the past three decades; a significant target in research since the discovery of multiple opioid receptors has been to develop highly potent and selective opioid receptor peptidomimetics that overcome the problems related to scarce bioavailability, enzymatic degradation, and low safety profile of natural peptides. Peptide drug design is a high multidisciplinary area that often relies on the state-of-the-art of organic chemistry, pharmacology, and biochemistry, computational methods and biophysical methods for determining the structural, conformational, topographical, and dynamic properties of designed ligands. With the aim to explore the recent advancements in opioids research, in this chapter, particular attention has been paid on the structural modifications of natural opioid peptides to obtain potent, selective, and stable opioid agonists. In addition, we focused our attention on μ/δ mixed agonists and novel approaches based on multitarget ligands, as discussed in section "Future Perspectives and Conclusions."

KW - opioid receptor agonists antinociceptive profile peptidomimetics topographical constraints structure-activity relationship

UR - http://www.scopus.com/inward/record.url?scp=84946182118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946182118&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-63462-7.00002-6

DO - 10.1016/B978-0-444-63462-7.00002-6

M3 - Article

AN - SCOPUS:84946182118

VL - 46

SP - 27

EP - 68

JO - Studies in Natural Products Chemistry

JF - Studies in Natural Products Chemistry

SN - 1572-5995

ER -